Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2018 Feb 15;45(8):1372–1381. doi: 10.1007/s00259-018-3941-3

Figure 3.

Figure 3

Quantitative results of PET imaging after injection of 89Zr-Df-daratumumab or 89Zr-Df-IgG in Ramos and HBL-1 lymphoma models. At all of the time points, Ramos tumors displayed significantly higher uptake than HBL-1 tumors and the nonspecific tracer (p < 0.05; n = 4). The uptake of 89Zr-Df-daratumumab in the heart blood pool, liver, and kidney showed no significant difference between Ramos and HBL-1 models.